Dual targeting of TIGIT and VISTA in non-small-cell lung cancer immunotherapy

Authors

  • Alaa A. A. Aljabali Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, P.O. Box 566, Irbid, 21163, Jordan. E-mail: alaaj@yu.edu.jo https://orcid.org/0000-0002-9519-6338
  • Omar Gammoh Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, PO BOX 566, Irbid, 21163, Jordan https://orcid.org/0000-0001-8801-2652
  • Esam Qnais Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan https://orcid.org/0000-0002-6203-4527
  • Abdelrahim Alqudah Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa 13133, Jordan https://orcid.org/0000-0003-3721-8225
  • Vijay Mishra School of Pharmaceutical Sciences, Lovely Professional University, Phagwara (Punjab) 144411, India https://orcid.org/0000-0001-6542-2464
  • Yachana Mishra School of Bioengineering and Biosciences, Lovely Professional University, Phagwara (Punjab) 144411, India
  • Mohamed El-Tanani College of Pharmacy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, UAE https://orcid.org/0000-0002-4735-5445

DOI:

https://doi.org/10.17179/excli2025-8735

Keywords:

Non-small cell lung cancer, TIGIT, VISTA, Dual immune checkpoint blockade, Tumor microenvironment, T-cell exhaustion

Abstract

This study investigated the therapeutic impact of dual immune checkpoint inhibition targeting TIGIT and VISTA in non-small cell lung cancer (NSCLC). Current monotherapies have failed to produce consistent and durable responses owing to tumor heterogeneity and immune evasion. By evaluating the biological and immunomodulatory roles of TIGIT and VISTA, this study provides a rationale for their simultaneous blockade. Preclinical models have shown that this dual strategy not only revitalizes T-cell function but also alters the suppressive tumor microenvironment, leading to improved antitumor immunity in mice. Preliminary clinical data suggest potential survival benefits; however, the long-term outcomes and resistance dynamics remain uncertain. These findings suggest a paradigm shift toward precision-designed, multi-target immunotherapies. Future studies should integrate molecular profiling, adaptive clinical trial designs, and follow-up models to optimize patient selection and sustain therapeutic benefits.

Published

2025-08-28

How to Cite

Aljabali, A. A. A., Gammoh, O., Qnais, E., Alqudah, A., Mishra, V., Mishra, Y., & El-Tanani, M. (2025). Dual targeting of TIGIT and VISTA in non-small-cell lung cancer immunotherapy. EXCLI Journal, 24, 1100–1142. https://doi.org/10.17179/excli2025-8735

Issue

Section

Review articles

Categories

Most read articles by the same author(s)